Alma vs Hims & Hers
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health network connecting clients to in-network therapists; handles credentialing, billing, and insurance contracting for affiliated clinicians; one of largest US therapist networks.
About
Alma is a New York-based mental health company that operates a network of therapists and psychiatrists, providing them with the business infrastructure to run private practices while accepting insurance. Alma handles credentialing, billing, insurance contracting, and administrative tasks for affiliated clinicians, enabling therapists to focus on patient care rather than paperwork while earning more than they could through employment at a group practice. On the patient side, Alma makes it easier to find available in-network therapists — a persistent challenge in mental healthcare — through its searchable directory of affiliated providers across the country. Alma has built one of the largest networks of private practice therapists accepting insurance in the United States, with thousands of clinicians across most states. Founded in 2017, Alma raised over $220M from investors including Insight Partners, Tiger Global, and Optum Ventures. The company addresses both sides of the mental health access crisis: insufficient supply of providers and inadequate insurance reimbursement making private practice financially unviable.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
About
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.